In an adult patient on chronic hemodialysis or peritoneal dialysis with elevated intact parathyroid hormone, what is the target PTH range and recommended medical management?

PTH Management in Chronic Dialysis Patients

For adult patients on chronic hemodialysis or peritoneal dialysis, there is no single optimal PTH target, but patients with intact PTH progressively rising or persistently above the upper normal limit (approximately >65-70 pg/mL) should be evaluated and treated, with most evidence supporting a practical target range of 150-300 pg/mL for dialysis patients. 1, 2

Understanding the Evidence on PTH Targets

The 2017 KDIGO guidelines explicitly state that "the optimal PTH level is not known" for dialysis patients 1, 2. This represents a significant shift from rigid numerical targets. However, this doesn't mean PTH should be ignored—rather, treatment decisions should focus on trends (progressively rising levels) and persistently elevated values above normal limits.

Key distinction: The guidelines differentiate between pre-dialysis CKD patients (stages G3a-G5 not on dialysis) and dialysis patients (G5D), with different management approaches for each.

Practical Target Range

While KDIGO avoids strict targets, real-world evidence supports a functional range:

• Japanese guidelines suggest 60-180 pg/mL for dialysis patients, with mortality data supporting this range 3
• Observational data from Japanese dialysis patients showed the target range of 60-240 pg/mL was associated with lower cardiovascular disease risk over 10 years 4
• Recent 2025 data identified an inflection point at 193 pg/mL, below which mortality risk increases in an L-shaped curve, suggesting harm from over-suppression 5

The most clinically useful target for dialysis patients appears to be 150-300 pg/mL, balancing the risks of both over-suppression (adynamic bone disease, increased mortality) and under-treatment (bone disease, vascular calcification).

Medical Management Algorithm

Step 1: Evaluate and Correct Modifiable Factors

Before initiating PTH-lowering therapy, address 1, 2:

• Hyperphosphatemia: Target phosphorus 3.5-5.5 mg/dL
• Hypocalcemia: Maintain calcium 8.4-10.0 mg/dL
• High phosphate intake: Restrict dietary phosphate, considering source (animal vs. vegetable vs. additives)
• Vitamin D deficiency: Measure and replete 25-OH vitamin D

Critical pitfall: High phosphate intake can drive PTH elevation even without overt hyperphosphatemia, especially in earlier CKD stages 1. Don't wait for hyperphosphatemia to restrict dietary phosphate.

Step 2: Phosphate Management

• Limit dietary phosphate intake (animal protein, processed foods with phosphate additives) 1, 2
• Phosphate binders:
  • Restrict dose of calcium-based binders, especially if calcium >10.0 mg/dL, arterial calcification present, or PTH persistently low 2
  • Consider non-calcium-based binders (sevelamer, lanthanum) to avoid excess calcium exposure
  • Evidence shows that achieving PTH control improves phosphate control—in one study, 70% achieved phosphorus ≤5.5 mg/dL when PTH was controlled vs. only 46% when PTH remained elevated 6

Step 3: PTH-Lowering Therapy for Dialysis Patients (G5D)

For dialysis patients with elevated or rising PTH despite correcting modifiable factors 2:

Choose from:

• Calcimimetics (cinacalcet or etelcalcetide)
• Calcitriol or vitamin D analogs
• Combination therapy (calcimimetics + vitamin D analogs)

Calcimimetics are increasingly preferred because they:

• Lower PTH without raising calcium or phosphorus 7
• Reduce PTH by approximately 43% 7
• Etelcalcetide (IV) offers better adherence and tolerability than oral cinacalcet 7

Important caveat: The EVOLVE trial showed no mortality benefit from cinacalcet despite PTH lowering 2, 7. Treatment should focus on preventing severe hyperparathyroidism complications (bone disease, fractures, calciphylaxis) rather than expecting survival benefit.

Step 4: Reserve Active Vitamin D for Specific Situations

For pre-dialysis CKD (G3a-G5 not on dialysis): Do NOT routinely use calcitriol or vitamin D analogs 1, 2. Reserve for patients with CKD G4-G5 with severe and progressive hyperparathyroidism.

For dialysis patients: Vitamin D analogs are an option but carry risks of hypercalcemia and hyperphosphatemia 1. Use lower doses when combined with calcimimetics.

Step 5: Monitor for Over-Suppression

Avoid PTH <150 pg/mL based on:

• Increased mortality risk below this threshold 5
• Risk of adynamic bone disease 2, 8
• Higher prevalence of suppressed PTH (20-35%) in real-world practice 9

If PTH falls below 150 pg/mL:

• Reduce or stop calcimimetics
• Reduce or stop vitamin D analogs
• Consider switching to 1.50 mmol/L calcium dialysate (if using lower concentration)

Common Pitfalls

1. Treating a single elevated PTH value: Guidelines emphasize "progressively rising or persistently elevated" levels—don't overreact to one measurement 1

2. Ignoring phosphate intake when phosphorus is normal: High phosphate intake drives PTH even without hyperphosphatemia 1

3. Excessive calcium exposure: Limit calcium-based phosphate binders; excess calcium is harmful across all CKD stages 1

4. Over-suppressing PTH: PTH <150 pg/mL is associated with worse outcomes 5; some PTH elevation may be adaptive 1

5. Using vitamin D analogs routinely in pre-dialysis CKD: This is explicitly not recommended 1, 2

Treatment Failure

If PTH remains >600 pg/mL despite maximal medical therapy, consider parathyroid intervention 8:

• Parathyroidectomy (definitive)
• Percutaneous ethanol injection therapy (PEIT) for 1-2 glands
• Direct vitamin D injection (investigational)